Soleus Capital Management L.P. Increases Stake in Grifols, S.A. (NASDAQ:GRFS)

Soleus Capital Management L.P. boosted its position in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 46.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,605,425 shares of the biotechnology company's stock after purchasing an additional 2,083,722 shares during the quarter. Grifols comprises 3.1% of Soleus Capital Management L.P.'s investment portfolio, making the stock its 6th biggest position. Soleus Capital Management L.P. owned about 0.96% of Grifols worth $49,144,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of GRFS. R Squared Ltd purchased a new stake in Grifols in the 4th quarter worth approximately $28,000. Blue Trust Inc. raised its position in shares of Grifols by 254.0% during the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock valued at $52,000 after buying an additional 4,970 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Grifols by 354.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock valued at $60,000 after buying an additional 6,335 shares in the last quarter. First Trust Advisors LP purchased a new stake in shares of Grifols during the 4th quarter valued at $75,000. Finally, Envestnet Portfolio Solutions Inc. purchased a new stake in shares of Grifols during the 4th quarter valued at $77,000.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on GRFS shares. Morgan Stanley started coverage on shares of Grifols in a research report on Wednesday, February 12th. They set an "overweight" rating on the stock. Wall Street Zen upgraded shares of Grifols from a "hold" rating to a "buy" rating in a research report on Friday.

Grifols Trading Down 0.2%

NASDAQ:GRFS traded down $0.02 during trading hours on Friday, reaching $8.11. The company's stock had a trading volume of 1,008,606 shares, compared to its average volume of 1,161,185. The firm has a market capitalization of $5.58 billion, a price-to-earnings ratio of 6.93 and a beta of 0.44. The firm has a 50-day simple moving average of $7.31 and a 200-day simple moving average of $7.61. Grifols, S.A. has a 1 year low of $5.79 and a 1 year high of $9.96. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.